2f80: Difference between revisions

Revision as of 04:41, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2f80.png

Template:STRUCTURE 2f80

HIV-1 Protease mutant D30N complexed with inhibitor TMC114HIV-1 Protease mutant D30N complexed with inhibitor TMC114

Template:ABSTRACT PUBMED 16480273

About this StructureAbout this Structure

2F80 is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

ReferenceReference

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M., Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT, J Med Chem. 2006 Feb 23;49(4):1379-87. PMID:16480273

Page seeded by OCA on Tue Jul 29 04:41:40 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2f80.gif|left|200px]]
+{{Seed}}
+[[Image:2f80.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2f80|  PDB=2f80  |  SCENE=  }}
-'''HIV-1 Protease mutant D30N complexed with inhibitor TMC114'''
+===HIV-1 Protease mutant D30N complexed with inhibitor TMC114===
-==Overview==
+<!--
-The potent new antiviral inhibitor TMC-114 (UIC-94017) of HIV-1 protease (PR) has been studied with three PR variants containing single mutations D30N, I50V, and L90M, which provide resistance to the major clinical inhibitors. The inhibition constants (K(i)) of TMC-114 for mutants PR(D30N), PR(I50V), and PR(L90M) were 30-, 9-, and 0.14-fold, respectively, relative to wild-type PR. The molecular basis for the inhibition was analyzed using high-resolution (1.22-1.45 A) crystal structures of PR mutant complexes with TMC-114. In PR(D30N), the inhibitor has a water-mediated interaction with the side chain of Asn30 rather than the direct interaction observed in PR, which is consistent with the relative inhibition. Similarly, in PR(I50V) the inhibitor loses favorable hydrophobic interactions with the side chain of Val50. TMC-114 has additional van der Waals contacts in PR(L90M) structure compared to the PR structure, leading to a tighter binding of the inhibitor. The observed changes in PR structure and activity are discussed in relation to the potential for development of resistant mutants on exposure to TMC-114.
+The line below this paragraph, {{ABSTRACT_PUBMED_16480273}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 16480273 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_16480273}}
 ==About this Structure==
@@ Line 26: / Line 30: @@
 [[Category: Weber, I T.]]
 [[Category: Protein-inhibitor complex]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 03:34:17 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 04:41:40 2008''